Evaluating the use of low molecular weight heparin after lung surgery for cancer
Evaluation of the Effectiveness of Prophylactic Low Molecular Weight Heparin by Thromboelastography in Patients Who Underwent Lobectomy Due to Malignancy
Ege University · NCT06484231
This study is testing whether a blood thinner called low molecular weight heparin can help prevent complications in patients who have just had lung surgery for cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 25 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ege University (other) |
| Locations | 1 site (İzmir, Bornova) |
| Trial ID | NCT06484231 on ClinicalTrials.gov |
What this trial studies
This observational study assesses the effectiveness of low molecular weight heparin (LMWH) as a prophylactic treatment in patients who have undergone lobectomy due to malignancy. It utilizes thromboelastography to analyze blood samples collected at various stages: preoperative, postoperative day 1, and postoperative day 3. The study records patient characteristics, including age, gender, comorbidities, and details of the surgical procedure, alongside monitoring for postoperative complications.
Who should consider this trial
Good fit: Ideal candidates are patients who have undergone lobectomy for malignancy, either primary or secondary lung cancer.
Not a fit: Patients with known bleeding or coagulation disorders, or those on anticoagulant therapy, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve postoperative care and reduce complications in lung cancer patients undergoing lobectomy.
How similar studies have performed: While the use of LMWH for prophylaxis is common, the specific application of thromboelastography in this context is less established, making this approach somewhat novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who underwent lobectomy with thoracotomy or videothoracoscopy (VATS) due to malignancy (primary or secondary lung cancer) Exclusion Criteria: * Patients with a known diagnosis of bleeding or coagulation disorders * Patients receiving anticoagulant and antiplatelet therapy in the preoperative period * Patients who developed perioperative bleeding and therefore underwent perioperative blood and blood product replacement
Where this trial is running
İzmir, Bornova
- Ege University Faculty of Medicine — İzmir, Bornova, Turkey (RECRUITING)
Study contacts
- Principal investigator: Gizem Kececi Ozgur — Ege University Faculty of Medicine, Department of Thoracic Surgery
- Study coordinator: Gizem Kececi Ozgur, MD
- Email: gizem.kececi.1991@gmail.com
- Phone: +90 506 678 71 28
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Malignancy, malignancy, lobectomy, prophylaxis, thromboelastography